-
EnteroMedics Cut By Roth Capital On Utilization Growth
Thursday, June 9, 2016 - 8:39am | 308Read More...Roth Capital Partners analyst Chris Lewis has downgraded EnteroMedics Inc (NASDAQ: ETRM) shares to a Neutral rating from Buy citing lack of reimbursement limits and commercial adoption or utilization growth. The firm has a 12-month price target of $0.50 on the stock. The analyst said, "While we...
-
Biocept Is An Emerging Leader In Liquid Biopsy; Roth Starts At Buy
Monday, June 6, 2016 - 12:56pm | 301Read More...Roth Capital Partners analyst, Chris Lewis, believes that Biocept Inc (NASDAQ: BIOC) is an emerging leader in Liquid Biopsy. Therefore, he initiated coverage on the stock with a rate of Buy and kept a price tag of $1.20. The brokerage thinks that through its proprietary technology platform,...
-
Roth Concerned With 'Competitive, Pricing Uncertainties' At Cogentix Medical, Downgrades
Friday, May 6, 2016 - 10:04am | 242Read More...Cogentix Medical Inc (NASDAQ: CGNT) reported lower-than-expected 1Q16 revenues and GAAP net loss, but its operating cash generation was positive for the second consecutive quarter. Roth Capital Partners’ Chris Lewis downgraded the rating for the company from Buy to Neutral, with a price...
-
Feuerstein Not Excited About JPMorgan Biotech Conference
Monday, January 11, 2016 - 9:22am | 299Read More...JPMorgan's Annual Healthcare Conference is one of the largest gathering of healthcare companies, executives, investors, and other stakeholders and kicks off on Monday. Chris Lewis of Roth Capital Partners commented in a note on January 5 that he is expecting "a number of...
